Please assess the completion status of the following clinical trial:

Trial Title: A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women with advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy (surgery and/or radiotherapy).~* Patient has a histologically and/or cytologically confirmed diagnosis of estrogen receptor positive and/or progesterone receptor positive breast cancer~* Patient has HER2-negative breast cancer~* Patient has adequate bone marrow and organ function~Exclusion Criteria:~* Patient who received any CDK4/6 inhibitor.~* Patient has a known hypersensitivity to any of the excipients of LEE011 or letrozole~* Patients with inflammatory breast cancer.~* Patient who received any prior systemic anti-cancer therapy (including hormonal therapy and chemotherapy) for advanced breast cancer~* Patient is currently using other anti-cancer therapy~* Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects.~* Patient who has received radiotherapy ≤ 4 weeks~* Patient has a concurrent malignancy or malignancy within 3 years~* Patient has metastases to the central nervous system (CNS).~* Patient has a known history of HIV infection~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LEE011 +Letrozole (Type: EXPERIMENTAL): LEE011 - 3 weeks on 1 week off Letrozole 2.5mg - Once daily
- LEE011 + Tamoxifen (Type: EXPERIMENTAL): LEE011 - 3 weeks on 1 week off Tamoxifen 20mg - Once daily
- LEE011 + Fulvestrant (Type: EXPERIMENTAL): LEE011 - 3 weeks on 1 week off Fulvestrant 500 mg - Dosed every 28 days (Day 1 for each cycle) with 1 additional dose on Day 15 of Cycle 1

Based on this trial design, predict the completion outcome and termination type (if applicable).